Introduction
In 2001, the Human Genome Variation Society (HGVS) was launched with the mission to collect, document, and freely dis-tribute information on genomic variation [Horaitis and Cotton, 2004] . This group has developed publically available recommendations for variant nomenclature [http://www.HGVS.org] and has published a recent update [den Dunnen et al., 2016] . Having a standardized format for variant nomenclature is necessary for the unambiguous registration of variants in databases and correct reporting in clinical diagnostic reports that are used for subsequent treatment decisions [Antonarakis, 1998; den Dunnen and Antonarakis, 2000] . Correct description and interpretation of variants may be of high importance for the outcome of clinical trials.
Since the creation of variant databases in the 1990s, the use of collated data sets has been widespread. Many new locusspecific and comprehensive databases have been created, for example, the Human Genome Variation database, the catalogue of somatic mutations in cancer, or ClinVar [Cotton and Horaitis, 2002; Fredman et al., 2002; www.sanger.ac.uk/genetics/CGP/cosmic;  http://www.ncbi.nlm.nih.gov/clinvar/].
The number of identified sequence variants will increase rapidly with the widespread use of microarray analysis and next-generation sequencing in routine diagnostics. Correct registration of these findings in electronic databases has several advantages for health benefit research, for example, providing information on the clinical outcomes of patients with particular variants following specific drug treatments. In addition, automated sequence variant analysis and description software, such as Mutalyzer, helps the harmonized approach to mutation nomenclature [Wildeman et al., 2008] .
In the field of human genetics, many best practice guidelines and external quality assessment (EQA) providers have highlighted the need for correct variant nomenclature [Mueller et al., 2004; Touitou et al., 2009; Berwouts et al., 2011] . However, many laboratories performing tests in the field of molecular pathology have never been confronted with a harmonized way of reporting variants. Even the instruction manuals provided with commercial test kits often fail to describe variants using the recommended HGVS nomenclature. Raising awareness of HGVS nomenclature guidelines is therefore important for diagnostic laboratories as well as for industrial manufacturers.
Not only is the use of HGVS nomenclature important for correct interpretation of variant descriptions, a correct reference sequence and version number to which a variant is described cannot be omitted [Dalgleish et al., 2010] . For example, due to an update of the reference sequence (from NM 004333.1 to NM 004333.4) for the BRAF gene, the c.1796T>A p.(Val599Glu) variant was changed to c.1799T>A p.(Val600Glu). Providers of EQA in molecular oncology have promoted the use of the HGVS guidelines by scoring the nomenclature as part of the genotype or interpretation score. Each provider adheres to its own scoring system and there is no complete consensus between the different scoring systems.
This article describes the results of mutation nomenclature assessment made by four different EQA providers. While previous studies have focused on how many laboratories adhere to HGVS nomenclature guidelines, here, the type and impact of errors is discussed. Even though, correct identification of variants is also an important topic, this will not be handled in this study. Several other publications are available about this issue [Tembuyser et al., 2014; Tack et al., 2015] . This article will focus on the nomenclature of single nucleotide variants described in the course of two rounds of EGFR EQA schemes.
Materials and Methods
Four EQA providers were included in this study: European Society of Pathology (ESP), European Molecular Genetics Quality Network (EMQN), United Kingdom National External Quality Assessment Service (UK NEQAS) for Molecular Genetics, and Gen&Tiss. The EQA schemes are organized according to an accepted standard [van Krieken et al., 2013] Two scheme distributions for EGFR (MIM# 131550) variant analysis were evaluated per EQA provider. Participants received a number of samples for which variant analysis was requested. A diagnostic report was submitted for some of these cases based on the provided mock clinical information and the variant analysis results. For this study, one report per year and per participant was evaluated. Table 1 shows which variants were included in the EGFR EQA schemes for each provider. Only variant nomenclature according to the HGVS guidelines (version 2.121101) was considered as correct [van Krieken et al., 2013] .
Set Up of the EQA Schemes
The ESP EGFR EQA, French national scheme, and EMQN EGFR schemes are organized once a year. Ten samples are sent for variant analysis and for three of them submission of a clinical report was also required. Only one of the requested reports contained one or two single nucleotide variants [Patton et al., 2014] .
The French national scheme is organized by the Gen&Tiss consortium, in collaboration with the Biomedical Quality Assurance unit of the KU Leuven coordinates the ESP EQA schemes, it does not coordinate with the schemes [Nowak et al., 2012;  http://kras.eqascheme.org/; http://lung.eqascheme.org/]. The 2012 and 2013 schemes were funded by the French National Cancer Institute (INCa).
During 2012 and 2013, UK NEQAS for Molecular Genetics organized three EQA rounds, and in each round three tumor samples were distributed to the participants. For all samples, a mock diagnostic report was requested .
Nomenclature Evaluation Criteria
Only reports that actually contained a specific description of a variant were included in this study. For example, laboratories reporting a false negative or those who only described that an activating variant was found were excluded from the analysis.
Each report was evaluated separately and nomenclature errors were categorized. More than one category was assigned if more than one nomenclature error was made (combination of different errors). If a sample report contained a double EGFR gene variant, then both variants were evaluated separately. If a variant was described several times, each nomenclature description was taken into account for scoring.
Although both notations are considered correct according to HGVS, the use of a three-letter amino acid code rather than a one-letter code is the preferred notation for clinical reporting [den Dunnen and Antonarakis, 2000] . This study determines how many laboratories adhere to this preference.
Statistical Analysis
The statistical analysis was performed using SPSS version 22. Chisquared analyses were performed to compare the different groups. Alfa values were set at 5% and a Bonferroni correction was applied as necessary.
Results

ESP
The evaluated schemes (offered in March 2013 and June 2014) had 164 and 149 participating laboratories, respectively. However, because some laboratories failed to submit reports, or reported a false negative, or a vague definition of the variant (e.g., an activating variant was detected), the total number of evaluated reports was lower. The specific numbers for each variant are presented in Table 2 .
For these schemes, two single nucleotide variants were present in each report. The different errors for each specific variant are categorized and presented in Table 3 . Although not a true error, the use of one-letter codes versus three-letter codes for amino acids was also evaluated and the results are shown in Table 4 .
Table 2. Overview of the Diagnostic Reports that Could Not Be Included in the Evaluation
Reports that are not included in the analysis UK NEQAS for Molecular Genetics 55 (28%) 59 (26%) 18 (23%) 19 (27%) 42 ( The reference sequences and version numbers (NM 005228.3) were present in a small number of assessed reports, 31% in 2013 and 24% in 2014. Some laboratories (1% and 6%) mentioned the reference sequence but did not provide a version number.
UK NEQAS for Molecular Genetics
In the UK NEQAS for Molecular Genetics schemes, a higher percentage of reports was included in the analysis; 93% (56 reports) for the scheme of April 2012 and 98% (59 reports) for the scheme of October 2013 (Table 2) . Tables 3 and 4 
EMQN
The EMQN scheme is the largest with 244 participants in 2013 and 251 participants in 2014; 80% and 92% of the reports could be included in the analysis. The reports for these participants contained the description of the specific variant (Table 2) . Table 3 gives an overview of the most frequent errors made by the participating laboratories. Table 4 presents the details on the use of the one-or three-letter code.
Only 47% participants in 2013 and 40% of the participants in 2014 included the correct reference sequence and a version number in their reports.
The French National Gen&Tiss EQA Scheme
Each year 56 French laboratories are invited to participate, of which 11 did not take part in the EGFR scheme. Of the remaining laboratories, six in 2012 and four in 2013 reported results using nomenclature that could not be evaluated ( Table 2) .
The samples used in the scheme included one (2012) and two (2013) single nucleotide variants. Details of the errors made can be seen in Table 3 . Details on the use of the one-or three-letter code can be seen in Table 4 .
The correct inclusion of the reference sequence and its version number in the diagnostic report showed an increase between the EQA runs, 33% in 2012 and 46% in 2013; 18% and 24% did include the reference sequence but no version number.
Longitudinal Follow-Up
In both analyzed ESP EGFR EQA schemes, the c.2369C>T p.(Thr790Met) alteration was included. The participants performed significantly better in the second year than in the first year, when comparing the number of reports with nomenclature errors versus the number of reports with correct nomenclature in each year (global P-value = 0.016, α = 0.05). Pairwise comparison, where the specific number of errors was taken into account, revealed only a significant difference between the participants using the correct HGVS nomenclature and the participants with a single error in each year (P-value = 0.0033, α = 0.025).
Comparisons among Different EQA Providers
The EMQN and ESP EQA were provided during early 2013 and 2014, and the UK NEQAS for Molecular Genetics and Gen&Tiss schemes were organized in early 2012 and late 2013. Schemes that took place around the same time are compared with each other.
For EMQN and ESP, no significant difference could be identified in the number of laboratories that make a nomenclature mistake, in either of 2 years (P-value = 0.36 for EMQN/ESP-2013, P-value = 0.19 for EMQN/ESP-2014, α = 0.05).
Conversely, the number of laboratories with a nomenclature error show a trend toward a higher number of errors for the Gen&Tiss group compared to the UK NEQAS for Molecular Genetics group, both in 2012 and 2013 (respective P-values are 0.051 and 0.050, α = 0.05).
Looking at the correct inclusion of the reference sequence and its version number, ESP participants make significantly more errors compared to the EMQN participants in both years (2013 P-value: 0.015; 2014 P-value: 0.002 ; α = 0.05).
More participants of UK NEQAS for Molecular Genetics schemes correctly included the reference sequence than Gen&Tiss participants. In the first year, there was a trend toward significance (P-value = 0.051, α = 0.05) and in the second year, the difference was strongly significant (P-value < 0.001, α = 0.05).
Discussion
Using the HGVS guidelines for variant nomenclature is important for a number of reasons. Correct interpretation of a diagnostic report by the clinician can affect further decisions made on diagnosis or therapy. In addition, inclusion of patients whose test reports contain an ambiguous variant nomenclature description could have a negative influence on the outcome of a clinical trial. For example, a database with a variant described as G719A could be interpreted as a DNA variant (shift from guanine to adenine) or protein variant (shift from glycine to alanine). Today, there is a shift toward a new approach in clinical trials where patients are recruited from databases for their specific variants across different types of tumors [Berry, 2015] . Even though several guidelines are available on how to implement HGVS nomenclature, many laboratories still use outdated recommendations or do not use any standardized format [Antonarakis, 1998; den Dunnen and Antonarakis, 2000] . Traditional nomenclature, that is nomenclature devised prior to the publication of HGVS guidelines, is still widely used, frequently without inclusion of the correct HGVS nomenclature (Table 3 ). For pathogenic changes that were described before any variant nomenclature recommendations, a transition period was allowed. Mentioning both the HGVS and traditional nomenclature was recommended to ensure legibility for the clinician and compatibility with existing literature. This is, for example, the case in human genetics for cystic fibrosis [Berwouts et al., 2011] . For molecular pathology, this transition period is not applicable, as EGFR testing in a diagnostic setting started after the publication of nomenclature guidelines. Participation in EQA and better awareness among molecular pathology laboratories could increase the use of standardized HGVS nomenclature.
The inclusion of an appropriate reference sequence is also required in a diagnostic report [den Dunnen and Antonarakis, 2000; Ogino et al., 2007] . When the reference sequence (including version number) is not provided, mistakes may occur when a user unknowingly selects another reference sequence that is incorrect for the nomenclature used. A strong effort is needed to raise awareness for reporting of a reference sequence and its version number among diagnostic laboratories. The results of this study show that EMQN participants and UK NEQAS for Molecular Genetics score better than the ESP and Gen&Tiss EQA participants. Participants of EMQN and UK NEQAS for Molecular Genetics lose points from their genotype score when omitting the reference sequence, which has an impact on their scheme performance score. Conversely, the ESP EQA participants only lose points on the educational reporting score that has no impact on receiving a certificate for successful participation in the EQA scheme. The feedback given to the participants by the EQA providers is similar; however, the deductions for mistakes are more significant in the EMQN versus the ESP EQA scheme (Table 5) . Additionally, EMQN has organized EGFR gene EQA schemes since 2011, 2 years longer than the ESP, so it is hypothesized that their participants are more ready to conform to nomenclature standards due to this more stringent approach. Future analyses are necessary to find out whether the specific approach or a learning effect is at the basis of this difference. UK NEQAS for Molecular Genetics organizes many different molecular pathology EQA schemes and many laboratories participate in several schemes. There is consistency in the scoring across their schemes leading to laboratories receiving the same feedback in the different schemes in a short timeframe, so the learning effect is hypothesized to be faster when compared to the Gen&Tiss scheme, which is organized only once a year.
The results also suggest a positive trend for the approach of UK NEQAS for Molecular Genetics compared to Gen&Tiss when assessing the nomenclature. Indeed, UK NEQAS for Molecular Genetics gives more specific nomenclature feedback to their participants. The correct variant annotation is given to each lab that makes a nomenclature error. In contrast, the comment in the Gen&Tiss scheme is nonspecific, stating that the HGVS recommendations were not followed, without any further educational feedback. UK NEQAS for Molecular Genetics participants have been exposed to assessment of their use of variant nomenclature for longer as their schemes have been available since 2010. In addition, the group of participant laboratories is different in both schemes: exclusive French laboratories (Gen&Tiss) versus laboratories from different countries (UK NEQAS for Molecular Genetics) and a different distribution of molecular and pathology versus genetic laboratories.
HGVS guidelines recommend that the use of the one-or threeletter code for amino acids is equally correct. However, they advocate a preference for the three-letter code to avoid confusion. It is clear that a high percentage of laboratories use the one-letter code. Currently, EMQN and UK NEQAS for Molecular Genetics comment on this to the laboratories after each round and the results from these providers show a decrease in the use of the one-letter code from year 1 to year 2. The ESP and Gen&Tiss providers take no action on this issue and the number of laboratories using the one-letter code has increased over the 2 years. This suggests that the feedback about the amino acid code could influence the laboratories use of the preferred three-letter code.
The improvement in the two ESP EQA schemes suggests that the participants learn from the general comments and the individual feedback received after each EQA participation. However, the number of participants in these EQA schemes is limited and this analysis could not be repeated for another EQA provider for the EQA runs analyzed. HUMAN MUTATION, Vol. 00, No. 0, 1-6, 2016 In the end, the results show the benefit of nomenclature scoring during EQA schemes and support the use of detailed feedback when nomenclature mistakes are made in diagnostic reports. In addition, further efforts are needed to harmonize the marking between EQA providers.
Conclusion
Today, the consequences of using incorrect variant nomenclature are often low, because of the small risk of misinterpretation when considering a limited panel of clinically significant variants. As the number of variants and genes analyzed increases, databases will become more important in this process and the use of harmonized and homogeneous variant nomenclature will be necessary to ensure that the correct information is extracted. Additionally, omitting the version number of a reference sequence could lead to inconsistencies between different generations of patients, leading to potential confusion and errors when recruiting for clinical trials [Dalgleish et al., 2010] . Actions should be taken now, since the results from the different EQA schemes described in this study show that significant efforts are needed to improve the standardization of variant nomenclature reporting in molecular pathology laboratories. This article demonstrates the positive impact of the actions of the various EQA providers to improve the standards of nomenclature reporting used to describe sequence variants.
